Home › Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer
 

Keywords :   


Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer

2016-05-03 02:58:08| drugdiscoveryonline Home Page

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology target programmed cell death protein 1 (PD-1).

Tags: cancer candidate announce canine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Hurricane Leslie Graphics
05.10Hurricane Leslie Forecast Discussion Number 11
05.10Hurricane Leslie Wind Speed Probabilities Number 11
05.10Hurricane Leslie Public Advisory Number 11
05.10Summary for Hurricane Leslie (AT3/AL132024)
05.10Hurricane Leslie Forecast Advisory Number 11
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 23
More »